Lisa Blixt
YOU?
Author Swipe
View article: Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era
Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era Open
Individuals with chronic lymphocytic leukemia (CLL) face an increased risk for severe COVID-19. This study from Sweden, a country that only had a few mandatory restrictions at the onset of the pandemic, used 10 nationwide registers to comp…
View article: Uptake of the first to fifth doses of coronavirus disease 2019 vaccine in individuals with chronic lymphocytic leukaemia: A nationwide cohort study in Sweden
Uptake of the first to fifth doses of coronavirus disease 2019 vaccine in individuals with chronic lymphocytic leukaemia: A nationwide cohort study in Sweden Open
Objectives Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe coronavirus disease 2019 (COVID‐19) as well as impaired responses to COVID‐19 vaccination, which may be overcome by repeated booster vaccinations…
View article: Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023
Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023 Open
Introduction Due to disease- and treatment-related immune defects, patients with chronic lymphocytic leukemia (CLL) have an increased risk of severe disease and death from COVID-19, as well as impaired responses to SARS-CoV-2 vaccination. …
View article: Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden
Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden Open
This nationwide study, including mostly well-treated PLHIV, highlights the importance of vaccination with booster dose/s for effective protection against severe COVID-19 in PLHIV.KEY POINTPeople living with HIV compared to people without H…
View article: Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia Open
Not available.
View article: Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia Open
Patients with chronic lymphocytic leukemia (CLL) were at high risk early in the COVID-19 pandemic. The Omicron SARS-CoV-2 variant is considered less aggressive, but a significant fatality rate was recently reported from CLL register studie…
View article: Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination Open
Patients with chronic lymphocytic leukemia (CLL) are immunocompromised. 1 They are at high risk for developing severe COVID-19 [2][3][4] and mount suboptimal immunity after messenger RNA (mRNA) vaccination, 5,6 but they have slightly confl…
View article: T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial Open
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial *Ab baseline = 0.4 U/mL; seropositive >0.8 U/mL. a n = …
View article: Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial Open
Background Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate the safety and efficacy after two dose…